Evidence map›Paper›PMID 35263985›Full record

ArticleHaematologica2022

The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition.

Salomé Decombis, Antonin Papin, Céline Bellanger, Clara Sortais, Christelle Dousset, Yannick Le Bris, Thiphanie Riveron, Stéphanie Blandin, Philippe Hulin, Benoit Tessoulin and 5 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. A BAFFlingHaematologica · 2022
    Article
  8. Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Salomé DecombisNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France; L'Héma-NexT, i-Site NexT, Nantes, France; GDR3697 Micronit, CNRS.
Antonin PapinNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France; L'Héma-NexT, i-Site NexT, Nantes, France; GDR3697 Micronit, CNRS.
Céline BellangerNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France; L'Héma-NexT, i-Site NexT, Nantes, France; GDR3697 Micronit, CNRS.
Clara SortaisNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France; L'Héma-NexT, i-Site NexT, Nantes, France; GDR3697 Micronit, CNRS; Service d'Hématologie Clinique, Unité d'Investigation Clinique, CHU, Nantes.
Christelle DoussetNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France; L'Héma-NexT, i-Site NexT, Nantes, France; GDR3697 Micronit, CNRS; Service d'Hématologie Clinique, Unité d'Investigation Clinique, CHU, Nantes.
Yannick Le BrisNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France; L'Héma-NexT, i-Site NexT, Nantes, France; GDR3697 Micronit, CNRS; Service d'Hématologie Biologique, CHU, Nantes.
Thiphanie RiveronNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France; L'Héma-NexT, i-Site NexT, Nantes, France; GDR3697 Micronit, CNRS.
Stéphanie BlandinSFR-Santé, INSERM UMS016, CNRS UMS 3556, FED 4202, UNIV Nantes, CHU, Nantes.
Philippe HulinSFR-Santé, INSERM UMS016, CNRS UMS 3556, FED 4202, UNIV Nantes, CHU, Nantes.
Benoit TessoulinNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France; L'Héma-NexT, i-Site NexT, Nantes, France; GDR3697 Micronit, CNRS; Service d'Hématologie Clinique, Unité d'Investigation Clinique, CHU, Nantes.
Mathieu RouelNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France; L'Héma-NexT, i-Site NexT, Nantes, France; GDR3697 Micronit, CNRS.
Steven Le GouillNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France; L'Héma-NexT, i-Site NexT, Nantes, France; GDR3697 Micronit, CNRS; Service d'Hématologie Clinique, Unité d'Investigation Clinique, CHU, Nantes.
Agnès Moreau-AubryNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France; L'Héma-NexT, i-Site NexT, Nantes, France; GDR3697 Micronit, CNRS.
Catherine Pellat-DeceunynckNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France; L'Héma-NexT, i-Site NexT, Nantes, France; GDR3697 Micronit, CNRS.
David ChironNantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France; L'Héma-NexT, i-Site NexT, Nantes, France; GDR3697 Micronit, CNRS. david.chiron@univ-nantes.fr.
Inserm · FRCentre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers · FRCentre National de la Recherche Scientifique · FRMicronit Microfluidics (Netherlands) · NLUniversité d'Angers · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aggressive B-cell malignancies, such as mantle cell lymphoma (MCL), are microenvironment-dependent tumors and a better understanding of the dialogs occurring in lymphoma-protective ecosystems will provide new perspectives to increase treatment efficiency. To identify novel molecular regulations, we performed a transcriptomic analysis based on the comparison of circulating MCL cells (n=77) versus MCL lymph nodes (n=107) together with RNA sequencing of malignant (n=8) versus normal B-cell (n=6) samples. This integrated analysis led to the discovery of microenvironment-dependent and tumor-specific secretion of interleukin-32 beta (IL32β), whose expression was confirmed in situ within MCL lymph nodes by multiplex immunohistochemistry. Using ex vivo models of primary MCL cells (n=23), we demonstrated that, through the secretion of IL32β, the tumor was able to polarize monocytes into specific MCL-associated macrophages, which in turn favor tumor survival. We highlighted that while IL32β-stimulated macrophages secreted several protumoral factors, they supported tumor survival through a soluble dialog, mostly driven by BAFF. Finally, we demonstrated the efficacy of selective NIK/alternative-NFkB inhibition to counteract microenvironment-dependent induction of IL32β and BAFF-dependent survival of MCL cells. These data uncovered the IL32β/BAFF axis as a previously undescribed pathway involved in lymphoma-associated macrophage polarization and tumor survival, which could be counteracted through selective NIK inhibition.

Indexed as

B-Cell Activating FactorInterleukinsLymphoma, Mantle-CellProtein Serine-Threonine KinasesAdultCell Line, TumorHumansMacrophagesNF-kappa BNF-kappaB-Inducing KinaseTumor MicroenvironmentB-Cell Activating FactorIL32 protein, humanInterleukinsNF-kappa BNF-kappaB-Inducing KinaseProtein Serine-Threonine KinasesTNFSF13B protein, human

Identifiers

PMID35263985
PMCPMC9713562
OpenAlexW4220858439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.